Comparison of the efficacy of EGFR tyrosine kinase inhibitors erlotinib and low-dose osimertinib on a PC-9-GFP EGFR mutant non-small-cell lung cancer growing in the brain of nude mice

Yuki Katsuya, Kentaro Miyake, Takashi Higuchi, Hiromichi Oshiro, Norihiko Sugisawa, Shree R.A.M. Singh, Yasushi Goto, Ming Zhao, Robert M. Hoffman

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: Brain metastases are found in approximately 30% of patients with epidermal-growth-factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). We compared the efficacy of two EGFR-tyrosine kinase inhibitors (TKIs), erlotinib and osimertinib on a PC-9-GFP EGFR mutant NSCLC growing in the brain of nude mice. Materials and Methods: The brain metastasis models were randomized into five groups and treated for 15 days: Control; 5 mg/kg erlotinib; 50 mg/kg erlotinib; 0.5 mg/kg osimertinib; 5 mg/kg osimertinib. Tumor volume was evaluated by non-invasive fluorescence imaging. Results: Only 5 mg/kg osimertinib, a low-dose compared to the clinically-equivalent dose, showed significant tumor regression compared to the control. Conclusion: This study strongly supports the high activity of osimertinib for intracranial lesions of EGFR-mutant NSCLC.

Original languageEnglish
Pages (from-to)1027-1030
Number of pages4
JournalIn Vivo
Volume34
Issue number3
DOIs
Publication statusPublished - 2020 Jun
Externally publishedYes

Keywords

  • Erlotinib
  • Non-small cell lung cancer
  • Nude mice
  • Osimertinib
  • PC-9-GFP

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Fingerprint

Dive into the research topics of 'Comparison of the efficacy of EGFR tyrosine kinase inhibitors erlotinib and low-dose osimertinib on a PC-9-GFP EGFR mutant non-small-cell lung cancer growing in the brain of nude mice'. Together they form a unique fingerprint.

Cite this